Sorafenib Improves Survival in Metastatic Differentiated Thyroid Cancer

Sorafenib Improves Survival in Metastatic Differentiated Thyroid Cancer

TOP Highlights From ASCO 2013

Results from the phase 3 DECISION study showed that sorafenib significantly improved progression-free survival for patients with radioactive iodine–differentialted thyroid cancer.

Read the full story: ASCO Daily News

Last modified: July 22, 2021

Home
Issues
Special Issues
- Supplements
  - ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
    - Checkmate 9LA
    - Checkmate 227
- Guide to New FDA Approvals
Categories
Conference Correspondent
- ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Quick Quiz
CE
About

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive:

TOP Print Edition

TOP Weekly e‑Newsletter

I have reviewed and consent to the terms of TOP's Privacy Policy, and TOP has my permission to retain my information in its database, and to forward pertinent communications to me.